This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
DSIP (10 mg Vial)
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain for its ability to enhance slow-wave sleep[1]. Research indicates DSIP may improve sleep quality, normalize sleep architecture, reduce stress-related cortisol patterns, and support mood stabilization without next-day grogginess[2][3].
Quick Reference
What is DSIP?
Research overview based on the cited scientific literature.
• Goal: Support improved sleep quality, enhanced delta-wave (slow-wave) sleep, and stress modulation over time[2][3].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is DSIP studied?
DSIP acts as a neuromodulator of the sleep-wake cycle and stress response. Administration consistently increases delta-wave (slow-wave) sleep in EEG recordings[2], suggesting it promotes the initiation and maintenance of deep, non-REM sleep. DSIP readily crosses the blood-brain barrier to exert central effects[7] and may enhance inhibitory neuronal activity or modulate sleep-regulating brain regions. Additionally, DSIP attenuates ACTH and corticosterone release in response to stress, indicating an effect on the hypothalamic-pituitary-adrenal axis[8]. Unlike conventional sedatives, DSIP tends to normalize sleep architecture without next-day grogginess[3].
What does the research report about DSIP?
Observations from preclinical and clinical literature.
• A double-blind study in 14 participants with chronic insomnia reported improvements in night sleep and daytime performance[3].
• A separate double-blind study in 16 participants found only weak objective effects and no change in subjective sleep quality; the authors concluded that short-term treatment was unlikely to provide major therapeutic benefit[10].
• Shows potential for stress reduction and mood support through HPA axis modulation[8][9].
• Remarkably safe profile: animal studies found no lethal dose even at extremely high doses; human studies report only mild, transient side effects (occasional headache or nausea)[1][8].
• Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on DSIP?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
